Standard dosage	150–300 mg every 8 hours (immediate-release form)
	225–425 mg every 12 hours (extended-release form)
Contraindications	Absolute: Coronary artery disease or structural heart disease (left ventricular systolic dysfunction, left ventricular hypertrophy, valvular disease), based on the results of the Propafenone Multicenter Study [43] and an extrapolation of the results of the CAST trial [42]
	Relative: Significant bradycardia, significant hepatic impairment
Main drug interactions	Macrolides, quinolones, antifungals, protease inhibitors, antipsychotics (risk of QT prolongation and proarrhythmia)
Main side effects	Bradycardia, worsening of heart failure, drug-induced atrial and ventricular arrhythmias, organization of atrial fibrillation into 1:1 atrial flutter
Special points	Class IC agent (sodium channel blocker) with mild beta blocking activity.
	Can be used in patients with renal impairment.
	Generally prescribed with an AV nodal blocker (beta blocker, non-dihydropyridine calcium channel blocker) to prevent 1:1 atrial flutter.
	Generally requires a screening stress test and echocardiogram to rule out coronary artery disease and structural heart disease.
	Rest and/or exercise electrocardiogram within 1–2 weeks of drug initiation to screen for QRS widening (a sign of drug toxicity and risk of proarrhythmia).
Cost/cost-effectiveness	Generic (approximate cost $100–200 per month). Can be initiated on an outpatient basis.